TiGenix to present results of Crohn`s disease drug trial at ECCO
TiGenix will present results from its Phase III trial of Crohn`s disease drug, named Cx601, at the upcoming 12th Annual Congress of the…
Pharmaceuticals, Biotechnology and Life Sciences
TiGenix will present results from its Phase III trial of Crohn`s disease drug, named Cx601, at the upcoming 12th Annual Congress of the…
Portola Pharmaceuticals has signed a $150 million royalty deal with HealthCare Royalty Partners (HCR).
Coordinated by Union for International Cancer Control (UICC), World Cancer Day is this year taking place under the tagline ‘We can. I can.’ and explores how everyone – as a collective or as individuals – can do their part to reduce the global burden of cancer.
Swedish Orphan Biovitrum is negotiating with a private equity firm regarding a possible sale of its Partner Products business area excluding Kineret and Orfadin.
Allergan’s boss Brent Saunders said that the company plans to increase dividend on an annual basis over time.
DBV Technologies has completed a Phase IIA investigator-initiated clinical trial of Viaskin Milk for the treatment of milk-induced Eosinophilic Esophagitis (EoE) in children ages 4-17 has been completed.
U.S. Food and Drug Administration (FDA) has approved Bristol-Myers’s Opdivo injection, for treatment of urothelial carcinoma (mUC).
Japan IP High Court confirmed validity of Eli Lilly’s Alimta vitamin regimen patents, and has invalidated trials initiated by Sawai regarding Lilly’s vitamin regimen patents for Alimta.
With the goal of developing Turkey as an R&D and technology hub, the Government has put place a number of measures to stimulate expansion of biotechnology and biopharmaceutical activities.
UBM EMEA’s Pharmapack Europe 2017 has named the winners of the 2017 Pharmapack Awards on Wednesday, picking four innovations in the Exhibitor Innovation category, while two winners were chosen to get awards in the Health Product category.